Introduction
============

Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer, with incidence and mortality rates rising in both Western and Asian countries ([@ref-44]). Because of late diagnoses, the 5-year overall survival (OS) rate LUAD varies from 4 to 17% in line with the differences of stage and region, which is still very poor ([@ref-43]). At present, there is still no effective early diagnosis method for patients to receive timely treatment ([@ref-46]). Therefore, it is necessary to search for novel target molecules for improving the early diagnosis and treatment of LUAD.

Previous studies have found a strong link between neurotrophic receptor tyrosine kinase 2 (NTRK2) and psychiatric disorders, such as schizophrenia ([@ref-30]). Recent research advancement in the field revealed the relationship between NTRK2 and cancer biology. According to the ceRNA network, [@ref-11] found that NTRK2 is related to the prognosis of invasive breast cancer. Through constructing the coexpression modules by WGCNA, NTRK2 was proposed to play a key role in the recurrence of uveal melanoma ([@ref-38]). [@ref-22] demonstrated that activated NTRK2 alleles, especially the human tumor-associated QKI-NTRK2 fusion, could function together with Ink4a/Arf loss to promote astrocytoma formation. Furthermore, a recent study found that the interaction between differentiated glioblastoma cells and stem-like tumor cells via BDNF-NTRK2-VGF paracrine signaling accelerates tumor growth ([@ref-41]). Nevertheless, there were few investigations about the relationship between NTRK2 and lung cancer, particularly LUAD, so the effects and mechanisms of NTRK2 in LUAD require further research.

The purpose of our study was to evaluate the role and mechanism of NTRK2 in human LUAD. Through bioinformatics data analysis, NTRK2 was found to be significantly downregulated in LUAD tissues. In addition, the expression level and methylation site of NTRK2 were notably correlated with clinical characteristics and prognosis. Moreover, based on the two datasets [GSE6400](GSE6400) and [GSE54293](GSE54293) from Gene Expression Omnibus (GEO), we observed the high levels of NTRK2 in the anticancer treatment group, indicating that NTRK2 could be used as a biomarker in evaluating clinical efficacy. In addition, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@ref-17]) analysis of NTRK2-associated coexpression genes further indicated that NTRK2 played an important part in LUAD treatment.

Materials and Methods
=====================

Data acquisition and reanalysis using different bioinformatics tools
--------------------------------------------------------------------

The relevant bioinformatics data analysis of NTRK2 was obtained from several bioinformatics web resources, which were summarized in [Table S1](#supp-1){ref-type="supplementary-material"}. The flow diagram of NTRK2 screen is shown in [Fig. S1](#supp-1){ref-type="supplementary-material"}.

Oncomine is a cancer microarray or high-throughput sequencing data-mining platform, from which we can get gene expression signatures in human cancer tissues and cells ([@ref-26]). The data in Oncomine could be also linked into other public databases, such as GEO and The Cancer Genome Atlas (TCGA) ([@ref-16]). We conducted the comparison of NTRK2 expression across eight analyses between the LUAD and normal tissues. Additionally, Gene Expression Profiling Interactive Analysis (GEPIA) ([@ref-35]), GE-mini ([@ref-36]), Cancer RNA-Seq Nexus (CRN) ([@ref-19]) and UALCAN ([@ref-6]), four additional cancer microarray or high-throughput sequencing data-mining databases, were employed to verify the results.

Wanderer is an interactive viewer, providing gene expression and DNA methylation data in human cancer ([@ref-10]), which enables us to screen for the possible methylation sites in the NTRK2 DNA sequence and to analyze the correlation between clinical characteristic of LUAD patients and NTRK2 expression and methylation sites. For the prognostic analysis, the Kaplan--Meier Plotter, a tool that can be used to assess the effect of genes on survival ([@ref-40]), was utilized to describe the relationship between NTRK2 expression level, overall survival time (OS) and post-progression survival time (PPS). Further, the association between NTRK2 expression and disease-free survival (DFS) was completed through the GEPIA database.

Two datasets of the treatment-related transcriptome microarray, [GSE6400](GSE6400) ([@ref-42]) and [GSE54293](GSE54293) ([@ref-9]), were acquired from the GEO database ([@ref-2]). Subsequently, the effects of NTRK2 expression on the chemotherapy for LUAD were analyzed.

The expression and methylation of NTRK2 correlation analysis were implemented by MethHC, which provided the information of DNA methylation and gene expression in human cancer ([@ref-15]). For the relevance between the disease prognosis and the methylation sites of NTRK2, the MethSurv tool was employed ([@ref-21]).

Using the cBioportal web tool ([@ref-12]), genes coexpressed with NTRK2 in LUAD were downloaded. Then, the STRING database ([@ref-34]) and Cytoscape software ([@ref-25]) were used to complete the protein--protein interaction (PPI) network of these coexpression genes. Then, we utilized the DAVID bioinformatics resource ([@ref-14]) to conduct the GO and KEGG pathway analysis of NTRK2 coexpression genes in LUAD samples. The web tools of WebGestalt ([@ref-39]) and PATHVIEW ([@ref-20]) were used for building a graphic.

Statistical analyses
--------------------

The statistical tests were performed using SPSS 12.0 software (IBM Analytics). The results were expressed as the mean ± SD. Student *t* test, one-way ANOVA and K independent samples test were performed when appropriate. *P* \< 0.05 was considered statistically significant.

Results
=======

NTRK2 is downregulated in LUAD tissues
--------------------------------------

The NTRK family consists of three members, NTRK1, NTRK2 and NTRK3. Through the bioinformatics analysis of databases, we evaluated the transcriptional levels of NTRK family members in LUAD. First, we used the Oncomine database to observe the expression of NTRK1, NTRK2 and NTRK3 in eight LUAD datasets ([@ref-3]; [@ref-4]; [@ref-13]; [@ref-18]; [@ref-23]; [@ref-28]; [@ref-31]; [@ref-33]). The results showed that NTRK2 had significantly lower expression in LUAD through the comparison among nine datasets, whereas NTRK1 and NTRK3 showed no statistical significance ([Fig. 1A](#fig-1){ref-type="fig"}). Therefore, NTRK2 was chosen as the research target. To verify the trend, we examined the NTRK2 expression in LUAD by GEPIA and GE-mini, and we discovered the NTRK2 expression was clearly reduced in LUAD compared with the normal tissues ([Figs. 1B](#fig-1){ref-type="fig"} and [1C](#fig-1){ref-type="fig"}). In addition, the heatmap from CRN database further indicated the low expression of NTRK2 in LUAD tissues ([Fig. 1D](#fig-1){ref-type="fig"}). Next, given some activated oncogenes, such as Erb-B2 receptor tyrosine kinase 2 (ERBB2) and MET, have been demonstrated the driver roles in LUAD ([@ref-5]), we want to evaluate the association between NTRK2 and these oncogenes. The data from UALCAN revealed the significantly downregulated NTRK2 (*P* \< 0.01), upregulated ERBB2 (*P* \< 0.01) and upregulated MET (*P* \< 0.01) in LUAD tissues ([Fig. S2A](#supp-1){ref-type="supplementary-material"}). Spearman correlation analysis showed the negative association between the expression of NTRK2 and ERBB2 or MET ([Fig. S2B](#supp-1){ref-type="supplementary-material"}). Taken together, all of the above data suggested that the decreased expression of NTRK2 contributed to LUAD tumorigenesis, supporting its tumor-inhibiting function in LUAD.

![Analysis of NTRK2 expression levels in LUAD tissues.\
(A) The comparison of the messenger RNA (mRNA) expression of NTRK (NTRK1, NTRK2 and NTRK3) among eight datasets by comparing the surrounding normal lung tissues and LUAD. (B--D) The mRNA expression of NTRK2 was evaluated from the database GEPIA, GE-mini and CRN, respectively.](peerj-07-7125-g001){#fig-1}

NTRK2 expression is associated with the clinical characteristics of LUAD patients
---------------------------------------------------------------------------------

After determining the expression of NTRK2 in LUAD, we further analyzed the correlation between the NTRK2 expression level and the clinical characteristics of patients. Using the Wanderer database, we obtained a series of clinical data, and a summary of clinical characteristic parameters is provided in [Table 1](#table-1){ref-type="table"}. As shown in this table, NTRK2 expression was significantly associated with gender (*P* = 0.007), pathologic T (*P* = 0.021), pathologic M (*P* = 0.006) and age (*P* = 0.036). Then, the Kaplan--Meier Plotter tool was used to evaluate the effects of NTRK2 expression on OS and PPS, confirming that the downregulated of NTRK2 expression was significantly related to shorter OS (*P* = 0.00029) ([Fig. 2A](#fig-2){ref-type="fig"}) and PPS (*P* = 0.021) ([Fig. 2B](#fig-2){ref-type="fig"}). Furthermore, we found that low NTRK2 expression was associated with RFS (*P* = 0.012) through using the GEPIA database ([Fig. 2C](#fig-2){ref-type="fig"}). In conclusion, NTRK2 could be as a potential biomarker both for diagnosis and prognosis.

![The effects of NTRK2 expression on prognosis in LUAD patients.\
(A--B) The relationship between NTRK2 expression and OS and PPS, described by Kaplan--Meier Plotter. (C) The association between NTRK2 expression and RFS within the GEPIA database.](peerj-07-7125-g002){#fig-2}

10.7717/peerj.7125/table-1

###### The correlation between clinical characteristic parameters and the expression of NTRK2 in LUAD.

![](peerj-07-7125-g006)

  Variables                                          Number   Mean ± SD     *P*
  -------------------------------------------------- -------- ------------- -------
  Gender                                                                    0.007
   Male                                              179      5.25 ± 1.90   
   Female                                            212      5.78 ± 1.95   
  Radiation therapy                                                         0.640
   Yes                                               6        5.12 ± 1.31   
   No                                                89       5.48 ± 1.82   
  Kras mutation found                                                       0.454
   Yes                                               14       5.48 ± 1.89   
   No                                                34       5.88 ± 1.54   
  Pathologic T                                                              0.021
   T1/T1a/T1b                                        122      6.01 ± 1.94   
   T2/T2a/T2b                                        218      5.35 ± 2.01   
   T3                                                34       5.29 ± 1.43   
   T4                                                15       5.09 ± 1.52   
   TX                                                2        4.36 ± 1.56   
  Pathologic N                                                              0.875
   N0                                                252      5.52 ± 1.86   
   N1                                                71       5.59 ± 1.89   
   N2                                                61       5.55 ± 2.32   
   NX                                                5        4.85 ± 2.40   
  Pathologic M                                                              0.006
   M0                                                255      5.38 ± 1.85   
   M1/M1a/M1b                                        16       4.86 ± 2.20   
   MX                                                117      5.99 ± 2.04   
  Pathologic stage                                                          0.471
   Stage I/IA/IB                                     211      5.63 ± 1.89   
   Stage IIA/IIB                                     94       5.45 ± 1.78   
   Stage IIIA/IIIB                                   68       5.52 ± 2.25   
   Stage IV                                          17       4.89 ± 2.14   
  Race                                                                      0.758
   White                                             314      5.60 ± 1.92   
   Black or African American                         23       5.41 ± 2.26   
   Asian                                             5        5.07 ± 1.12   
  Tobacco smoking history                                                   0.097
   Current reformed smoker for \> 15 years           94       5.84 ± 2.06   
   Current reformed smoker for \< or = 15 years      131      5.38 ± 1.95   
   Current reformed smoker, duration not specified   2        5.15 ± 1.34   
   Lifelong non-smoker                               61       5.91 ± 1.75   
   Current smoker                                    91       5.21 ± 1.97   
  Age at initial pathologic diagnosis                                       0.036
   ≤60                                               125      5.25 ± 1.86   
   \>60                                              248      5.69 ± 1.94   
  EGFR mutation result                                                      0.303
   Exon 19 deletion                                  7        5.07 ± 1.26   
   L858R                                             3        6.47 ± 1.00   
   Other                                             9        5.94 ± 1.58   

The roles of NTRK2 in LUAD therapies
------------------------------------

For the purpose of identifying the exact function of NTRK2 in LUAD chemotherapy, two treatment-related transcriptome microarray datasets, [GSE6400](GSE6400) and [GSE54293](GSE54293), were obtained from the GEO database. Previous studies have demonstrated that actinomycin D ([@ref-1]) and MK2206 ([@ref-8]) were two promising antitumor drugs. In the [GSE6400](GSE6400) dataset, we discovered that the expression of NTRK2 was apparently higher in the actinomycin D treatment group than in the mannitol-control group (*P* = 0.008) ([Fig. 3A](#fig-3){ref-type="fig"}). In addition, for the [GSE54293](GSE54293) dataset, the AKT inhibitor MK2206 could enhance the NTRK2 expression levels significantly (*P* = 0.009) ([Fig. 3B](#fig-3){ref-type="fig"}). Collectively, the findings observed above suggested that NTRK2 might enhance the response of cancer cells to the chemotherapeutics.

![The influence of NTRK2 on the therapeutic response of LUAD patients.\
(A) The [GSE6400](GSE6400) dataset acquired from the GEO database was employed to estimate the impacts of NTRK2 expression on LUAD therapy both in the actinomycin D treatment group and the mannitol-control group. (B) In the treatment-related microarray [GSE54293](GSE54293) dataset, the influence of NTRK2 expression on AKT inhibitor MK2206 treatment was evaluated.](peerj-07-7125-g003){#fig-3}

The relationship between NTRK2 methylation and the clinical characteristics of LUAD patients
--------------------------------------------------------------------------------------------

It is well-known that there is a negative correlation between DNA methylation and gene expression ([@ref-29]; [@ref-47]). From the MethHC database, we observed that global NTRK2 methylation was significantly higher in LUAD samples compared with normal samples (*P* \< 0.005) ([Fig. 4A](#fig-4){ref-type="fig"}) and was negatively related to its expression (*P* = 0.000) ([Fig. 4B](#fig-4){ref-type="fig"}), which gives further support for the low expression of NTRK2 in LUAD. Subsequently, the methylation site cg03628748 was screened out of the data (*P* = 4.35E-12) ([Table S2](#supp-1){ref-type="supplementary-material"}) acquired from the Wanderer database. Then, the relationship between cg03628748 and the clinical characteristics of LUAD patients was examined, and results showed that cg03628748 was significantly related to Kras mutation (*P* = 0.038) and pathologic T (*P* = 0.000) ([Table 2](#table-2){ref-type="table"}). Moreover, there was a significant negative correlation between higher methylation value of cg03628748 and shorter OS in LUAD patients (*P* = 0.034), which was analyzed by using the web tool of MethSurv ([Fig. 4C](#fig-4){ref-type="fig"}).

![The relationship between NTRK2 methylation and the clinical characteristics of LUAD patients.\
(A) Global NTRK2 methylation in LUAD samples compared with the normal samples analyzed by MethHC database. (B) The association between global NTRK2 methylation and its expression in LUAD samples using the MethHC database. (C) The impact of the methylation site cg03628748 in NTRK2 on OS in LUAD patients as analyzed by the MethSurv web tool.](peerj-07-7125-g004){#fig-4}
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###### The correlation between clinical characteristics of patients and the methylation site cg03628748 in NTRK2 in LUAD.

![](peerj-07-7125-g007)

  Variables                                          Number   Mean ± SD      *P*
  -------------------------------------------------- -------- -------------- -------
  Gender                                                                     0.123
   Male                                              189      0.32 ± 0.14    
   Female                                            219      0.30 ± 0.14    
  Radiation therapy                                                          0.112
   Yes                                               7        0.22 ± 0.097   
   No                                                96       0.31 ± 0.14    
  Kras mutation found                                                        0.038
   Yes                                               16       0.38 ± 0.18    
   No                                                34       0.28 ± 0.13    
  Pathologic T                                                               0.000
   T1/T1a/T1b                                        127      0.26 ± 0.11    
   T2/T2a/T2b                                        227      0.32 ± 0.14    
   T3                                                36       0.35 ± 0.16    
   T4                                                15       0.30 ± 0.15    
   TX                                                3        0.23 ± 0.17    
  Pathologic N                                                               0.464
   N0                                                261      0.31 ± 0.14    
   N1                                                75       0.30 ± 0.13    
   N2                                                62       0.30 ± 0.14    
   NX                                                8        0.24 ± 0.11    
  Pathologic M                                                               0.183
   M0                                                264      0.31 ± 0.14    
   M1/M1a/M1b                                        17       0.27 ± 0.16    
   MX                                                123      0.29 ± 0.13    
  Pathologic stage                                                           0.746
   Stage I/IA/IB                                     218      0.31 ± 0.14    
   Stage IIA/IIB                                     102      0.31 ± 0.13    
   Stage IIIA/IIIB                                   68       0.31 ± 0.14    
   Stage IV                                          19       0.27 ± 0.16    
  Race                                                                       0.214
   White                                             325      0.30 ± 0.13    
   Black or African American                         29       0.27 ± 0.12    
   Asian                                             5        0.37 ± 0.14    
  Tobacco smoking history                                                    0.075
   Current reformed smoker for \> 15 years           101      0.31 ± 0.15    
   Current reformed smoker for \< or = 15 years      135      0.32 ± 0.14    
   Current reformed smoker, duration not specified   2        0.39 ± 0.022   
   Lifelong non-smoker                               62       0.26 ± 0.12    
   Current smoker                                    96       0.31 ± 0.14    
  Age at initial pathologic diagnosis                                        0.644
   ≤60                                               131      0.30 ± 0.14    
   \>60                                              259      0.31 ± 0.13    
  Residual tumor                                                             0.542
   RX                                                16       0.31 ± 0.15    
   R0                                                271      0.31 ± 0.14    
   R1                                                10       0.26 ± 0.093   
  EGFR mutation result                                                       0.082
   Exon 19 deletion                                  7        0.18 ± 0.063   
   L858R                                             3        0.28 ± 0.17    
   Other                                             9        0.33 ± 0.13    

Functional enrichment analysis of NTRK2-associated coexpression genes
---------------------------------------------------------------------

Using the cBioPortal database, 15,146 genes that were notably coexpressed with NTRK2 in the LUAD samples were acquired. The volcano plot was established for exhibiting between the altered and unaltered NTRK2 expression group ([Fig. 5A](#fig-5){ref-type="fig"}). Next, we singled out 219 NTRK2-associated codifferentially expressed genes (co-DEGs) with the criteria of *P* value \< 0.05 and \|log Ratio\| ≥ 2 ([Table S3](#supp-1){ref-type="supplementary-material"}). Then, a PPT network of the co-DEGs was performed by using the STRING database and Cytoscape software ([Fig. 5B](#fig-5){ref-type="fig"}). For the purpose of comprehending the biological function for these co-DEGs, GO and KEGG analyses were conducted by the WebGestalt and PATHVIEW web tools, respectively. The biological processes showed that these co-DEGs were mainly connected with biological regulation and metabolic processes ([Fig. 5C](#fig-5){ref-type="fig"}). For the analysis of cellular components, the coexpression genes were mainly localized on cell membranes ([Fig. 5D](#fig-5){ref-type="fig"}). For molecular function, protein binding was primarily enriched for these coexpression genes ([Fig. 5E](#fig-5){ref-type="fig"}). Furthermore, the KEGG pathway demonstrated that these genes were involved in the process of xenobiotics and drug metabolism by cytochrome P450 ([Table S4](#supp-1){ref-type="supplementary-material"}).

![Functional enrichment analysis of NTRK2-associated co-DEGs in LUAD.\
(A) The coexpression genes of NTRK2 were shown as volcano plot. (B) The PPI network of NTRK2-associated co-DEGs as completed by the STRING and Cytoscape software. (C--E) The GO analysis of NTRK2 associated co-DEGs including biological processes, cellular components and molecular function.](peerj-07-7125-g005){#fig-5}

Discussion
==========

This is the first study which presents comprehensive bioinformatic analysis of different public datasets that NTRK2 was identified as anti-oncogene in LUAD and could be used as a potential biomarker. Using the TCGA data from several databases, we found that NTRK2 expression was markedly decreased in LUAD tissues. The patients with downregulated NTRK2 expression and higher methylation values often had shorter OS, PPS and RFS.

Neurotrophic receptor tyrosine kinase 2 belongs to the NTRK family and has been previously shown to have an important impact on the development of the nervous system ([@ref-7]). However, recent studies have demonstrated the possible role of NTRK2 in the development of cancer. Neurotrophic receptor tyrosine kinase 2 activation cooperates with PTEN deficiency through the activation of both the JAK--STAT3 and PI3K-AKT pathways to induce aggressiveness, resistance to current therapies and poor prognosis of T-cell acute lymphoblastic leukemia ([@ref-45]). Currently, NTRK fusion mutations have been reported to associate with oncogenic activation in various signaling pathways, such as AKT and MAPK, across multiple tumors ([@ref-32]). Moreover, NTRK fusions were connected with poor survival in lung cancers ([@ref-27]). Interestingly, the reports seemed contrary to our results; this phenomenon might be explained by following reasons. First, it is known that different diseases or subtypes of tumors have diverse pathological states, which can change genes^,^ functions. On the other hand, the structure, constitution and condition of genes may transformed, such as gene mutation, accompany with gene fusions. Furthermore, NTRK fusions are thought to occur at a low frequency across multiple tumor types ([@ref-37]). Additionally, although NTRK fusions were observed in rare cancer types, such as congenital infantile fibrosarcoma and secretory breast carcinoma, the occurrence in common cancers has been largely unexplored ([@ref-24]). Additionally, the difference in results might be on account of study designs or different patient populations, indicating international, multicenter randomized controlled, clinical research is needed for further study.

In the present study, GO and KEGG pathway analyses indicated that genes coexpressed with NTRK2 were mainly enriched in the processes of xenobiotics and drug metabolism. Moreover, NTRK2 expression was much higher in drug therapy groups in both the [GSE6400](GSE6400) and [GSE54293](GSE54293) datasets. Therefore, up-regulating NTRK2 expression to promote drug metabolism might be the mechanism that explains this phenomenon.

Nevertheless, there were several limitations to our study. First, the flow chart of analysis on the roles of NTRK2 in LUAD tumorigenesis was not strong enough, and should be further verified externally in diverse cohorts. Additionally, further validation of the roles of NTRK2 in multicenter clinical trials and prospective research is required. For the TCGA database, the included ethnicities were primarily white and black, and more studies are needed to confirm whether the findings are appropriate for other ethnic groups. Furthermore, more prognostic variables must be included to improve performance.

Conclusion
==========

In conclusion, our study illustrated that NTRK2 was a putative cancer suppressor gene and could serve as a promising biomarker in tumorigenesis and treatment of LUAD patients. Furthermore, DNA hypermethylation has been demonstrated to be one of the mechanisms for the low-expressed NTRK2 in LADC. Understanding its detailed function and mechanisms in LUAD biological processes would provide promising insights for the prognostic and therapeutic value.
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Figure S1. A Flow chart of analysis on the roles of NTRK2 in LUAD tumorigenesis.

Figure S2. The negative association between the expression of NTRK2 and ERBB2 or MET in LUAD.

Table S1: The main bioinformatics tools applied to analyze the role of NTRK2 in LUAD biological processes.
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